Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
981-1000 of 1,743 trials

Metastatic Melanoma: Early Detection of Side Effects

We are investigating whether a special imaging technique can help identify early side effects in patients receiving immune therapy for metastatic melanoma. This study aims to improve monitoring of immune-related side effects.

Malignant Melanoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ependymoma Treatment: SIOP Ependymoma II Program

We are exploring new chemotherapy options and surgical techniques for children and young adults with ependymoma. Our goal is to improve survival rates and treatment effectiveness compared to standard methods.

Ependymoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Small Cell Lung Cancer: Durvalumab Immunotherapy

We are studying whether durvalumab can help frail patients with limited small cell lung cancer live longer without disease progression after receiving thoracic chemoradiotherapy. The trial also examines the treatment's safety and its effects on quality of life.

Limited Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Takayasu Arteritis: Infliximab vs. Tocilizumab

We are studying whether Infliximab is more effective than Tocilizumab for patients with refractory or relapsing Takayasu arteritis. The goal is to see if it helps reduce disease activity and steroid use.

Takayasu's Arteritis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyRheumatology

Glibenclamide for High Blood Sugar in Premature Infants

We are studying whether an oral suspension of glibenclamide can help control high blood sugar in premature infants under 1500 grams. The trial will also look at its safety and effects on growth.

Neonatal Hyperglycemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyPediatrics

Non-Ischemic Dilated Cardiomyopathy: SECRET-HF Treatment

We are exploring whether infusions of a cell-derived product can improve heart function in patients with non-ischemic dilated cardiomyopathy. This study aims to find new treatment options for this condition.

Non-ischemic Dilated Cardiomyopathy>2 yearsSafety phase (I)Cardiology

Primary Hyperoxaluria: DCR-PHXC Injection Study

We are evaluating a new injection for patients with Primary Hyperoxaluria to see how it affects kidney function and overall safety. The study also looks at its impact on kidney stones and quality of life.

Primary Hyperoxaluria>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNephrology

Multiple Myeloma: SABLe Study with Selinexor

We are investigating a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The study aims to evaluate how well the treatment works and its effects on quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Multiple Sclerosis: Siponimod Therapy Study

We are exploring how siponimod affects inflammation in patients with active secondary progressive multiple sclerosis. The study aims to understand its impact on disease progression and patient health over time.

Progressive Multiple Sclerosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesNeurology

Advanced Colorectal Cancer: pTTL Immunotherapy

We are testing a new T cell immunotherapy called pTTL for patients with advanced colorectal cancer. This study aims to see how well it works and its safety in humans.

Colorectal Cancer>2 yearsSafety phase (I)Oncology

Colorectal Cancer: FAPI-PET Imaging Study

We are investigating whether FAPI-PET imaging can help detect tumor-associated fibrosis in patients with colorectal peritoneal metastases. This may improve diagnosis and treatment planning.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)GastroenterologyOncology

Relapsing Multiple Sclerosis: CYB704 vs. Ocrevus

We are comparing a new biosimilar treatment to Ocrevus for people with relapsing multiple sclerosis. The study aims to evaluate how well it works and its safety profile.

Multiple Sclerosis Relapse>2 yearsConfirmation phase (III)Neurology

Elderly Primary CNS Lymphoma: High-Dose Chemotherapy Study

We are comparing a high-dose chemotherapy followed by stem cell transplantation to standard chemotherapy for elderly patients with primary CNS lymphoma. The goal is to see which treatment leads to better survival and quality of life.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Viral Infections After Stem Cell Transplant: Multispecific T-Cell Therapy

We are studying a new treatment using multispecific T-cells for patients with viral infections that resist chemotherapy after stem cell transplantation. The goal is to see if this therapy can improve symptoms and overall health.

Viral Infections After Stem Cell Transplant>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesHematologyInfectious DiseasesOncology

Prostate Cancer: New Radioactive Treatment Study

We are testing a new radioactive drug for adults with metastatic castration-resistant prostate cancer who have not had chemotherapy. The study will assess the safety and how well the treatment works in these patients.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Standard MedicinesOncology

Advanced Breast Cancer: Trastuzumab Deruxtecan vs. CDK4/6 Inhibitors

We are studying whether trastuzumab deruxtecan is more effective than a combination of CDK4/6 inhibitors and endocrine therapy for patients with HR-positive, HER2-low advanced breast cancer. This research aims to improve treatment options for this specific group of patients.

Locally Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOncology

Advanced Solid Tumors: STP938 Treatment Study

We are testing a new drug called STP938 in adults with advanced solid tumors, including those with a specific type of ovarian cancer. The study aims to evaluate the safety of this treatment.

Ovarian CancerSolid Tumors>2 yearsSafety phase (I)Oncology

PRT7732 for Advanced Solid Tumors with SMARCA4 Mutation

We are testing a new oral medication for patients with advanced or metastatic solid tumors that have a specific genetic mutation. The goal is to see if it can help improve treatment outcomes.

Esophageal, Gastric, or Gastroesophageal Junction AdenocarcinomaEsophageal, Gastric, or Gastroesophageal Junction Squamous Cell CarcinomaNon-Small Cell Lung Cancer (NSCLC)>2 yearsSafety phase (I)Oncology

Duchenne Muscular Dystrophy: Satralizumab Study

We are studying the effects of satralizumab in children and teens with Duchenne muscular dystrophy. This trial aims to see if it is safe and how it impacts bone health and metabolism.

Duchenne Muscular Dystrophy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyNeurologyPediatrics

Anesthesia in Young Children: Low-Dose vs. Standard Sevoflurane

We are comparing the effects of low-dose sevoflurane combined with dexmedetomidine and remifentanil against standard sevoflurane anesthesia on cognitive development in children under 2 years old. The goal is to see which method supports better brain development as they grow.

General Anesthesia in Young Children>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics